Drug intelligence / Profile preview

IMW-029

Development stage: Unknown
Lead developer: Immunowake
Modality: Antibody-Based Therapeutics

Overview

IMW-029 is an investigational antibody drug developed by Immunowake for the treatment of neoplasms (cancers). It is currently in early clinical development, with its highest reported phase being Phase 1. The specific mechanism of action and molecular target have not been publicly disclosed as of the latest available information. The drug represents a novel approach from Immunowake, a company focused on innovative therapies for patients who do not respond to traditional immunotherapy methods[1][3].

Other names: IMW-029IMW029IMW 029

Beyond the preview

Go deeper on IMW-029.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMW-029.

Explore the full profile